FDA awards EpiVax $1.1 million research contract

PROVIDENCE – Biotechnology company EpiVax Inc. received $1.1 million in funding Wednesday from the U.S. Food and Drug Administration to further research efforts in the field of informatics and immunology. The company has been pursuing development of a COVID-19 vaccine and personalized cancer vaccines. The FDA's Office of Generic Drugs in the Center of Drug…

Register to keep reading or subscribe today and receive unlimited access.
Register Now Already a Subscriber? Login now